Fiche société
Disphar International B.V.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications1liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Teysuno (S1) in combination with epirubicin and oxaliplatinThe goal of the current study was to investigate the safety and determine the maximum tolerated dose (MTD) of S-1 in combination with oxaliplatin and epirubicin in patients with advanced or metastatic solid tumors. | Cancer | Phase 1 | À vérifier | À vérifier | |
| Teysuno (S1) in combination with epirubicin and oxaliplatinThe goal of the current study was to investigate the safety and determine the maximum tolerated dose (MTD) of S-1 in combination with oxaliplatin and epirubicin in patients with advanced or metastatic solid tumors. | Cancer | Phase 1 | À vérifier | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Teysuno (S1) in combination with epirubicin and oxaliplatin | Cancer | Phase 1 | NCT02867397 | Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors | COMPLETED |
Publications
1| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Teysuno (S1) in combination with epirubicin and oxaliplatin | Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report. | Oncology letters |